Clinical Trial

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the correct dose and safety of combining two new cancer drugs, loncastuximab tesirine and venetoclax, as a treatment for relapsed or refractory B cell lymphoma.These drugs are used to treat some lymphomas, but have not yet been tested in combination for the treatment of lymphoma. The main goal of this study is to determine the safety of the combination.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2026-11 2026-06-06
minor Completion pushed: 2026-06 -> 2026-11 2026-06-06
Trial Details
NCT Number NCT05053659
Lead Sponsor Paolo Caimi, MD
Conditions Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Enrollment 23 participants
Start Date 2022-06-20
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-05